Caris has received U.S. FDA Breakthrough Device designation for MI Transcriptome companion diagnostic (CDx) test. Designed to detect gene fusions in solid tumors, the test is intended to assist clinicians in identifying patients who may benefit from treatment with specific targeted therapies.

Caris has acquired Pharmatech, Inc., and is changing the paradigm from the traditional physician outreach model to a real-time approach where patient identification is completed at the lab and the physician is informed so that the patient can be enrolled days earlier, and remain in the local physician's care, without having to travel to a large central trial site.

Although liquid biopsy (blood) profiling to detect and characterize cancer from fragments of circulating tumor DNA continues to emerge as a clinically useful tool (PLoS1, NILE2, etc.), solid tissue profiling remains the gold standard and produces the most reliable results.